Thomas M. Soloway, a newly reported director at Azora Therapeutics, Inc., filed a Form 3 Initial Statement of Beneficial Ownership with the SEC on November 10, 2026, reflecting an event date of November 3, 2026.

Key Highlights

  • Reporting person: Thomas M. Soloway, identified as a Director of Azora Therapeutics, Inc.
  • Event date: The date of the event requiring the statement was November 3, 2026.
  • No securities held: According to the filing, "No securities are beneficially owned."
  • Tables empty: Both Table I (non-derivative securities) and Table II (derivative securities) contain no entries.
  • Filing method: The form was filed by one reporting person, signed by Matthew Davidson as Attorney-in-Fact on November 10, 2026.
  • Issuer: Azora Therapeutics, Inc. (DE), listed under ticker AZR, with the filing referencing NASDAQ:AZR.

Soloway Reports No Beneficial Ownership Upon Joining Azora Therapeutics Board

According to the filing, Thomas M. Soloway submitted a Form 3 Initial Statement of Beneficial Ownership in connection with his role as a Director at Azora Therapeutics, Inc. (NASDAQ:AZR). The statement was triggered by an event dated November 3, 2026, and was filed with the SEC on November 10, 2026. Soloway's address on the filing is listed as c/o Azora Therapeutics, Inc., 16501 Ventura Blvd., Suite 400, Encino, California 91436.

The filing discloses that Soloway holds no beneficial ownership of any securities in the issuer. Table I, which covers non-derivative securities beneficially owned, and Table II, which covers derivative securities such as puts, calls, warrants, options, and convertible securities, are both reported as empty. The filing explicitly notes: "No securities are beneficially owned."

The form was signed by Matthew Davidson as Attorney-in-Fact, with an attached Exhibit 24 described as a Power of Attorney. The filing was submitted by one reporting person and is not an amendment to a prior filing, as no original filing date is listed in the amendment field.

What Was Disclosed

Thomas M. Soloway, a Director at Azora Therapeutics, Inc., filed an initial beneficial ownership statement reporting no holdings of any securities, either direct, indirect, non-derivative, or derivative, as of the November 3, 2026 event date.